Abstract We investigated the occurrence, diversity and molecular epidemiology of genes coding for acquired AmpC β-lactamases (qAmpC) among clinical isolates of Enterobacteriaceae lacking inducible chromosomal AmpCs in Portugal. A total of 675 isolates non-susceptible to broad-spectrum cephalosporins obtained from four hospitals and three community laboratories during a 7-year period (2002)(2003)(2004)(2005)(2006)(2007)(2008) were analysed. The presence of genes coding for qAmpC was investigated by phenotypic criteria, polymerase chain reaction (PCR) and sequencing. Bacterial identification, antibiotic susceptibility testing, conjugation assays and clonal analysis were performed by standard procedures. The presence of bla qAmpC genes was detected in 50 % (50/100; 41 Klebsiella pneumoniae, 5 Escherichia coli , 4 Klebsiella oxytoca ) of the presumptive qAmpC producers. DHA-1, detected in those species, was the most prevalent qAmpC (94 %, 47/50), being identified since 2003 and throughout the studied period in different institutions. Despite the high clonal diversity observed, three DHA-1-producing Klebsiella spp. clones were more frequently identified. CMY-2 (6 %, 3/50) was observed in B1-E . coli clones. Conjugative transfer was only observed in one (2 %) CMY-2-producing isolate. Most qAmpC producers (94 %, 47/ 50) co-expressed SHV-type and/or OXA-1 or CTX-M-32 extended-spectrum β-lactamases (ESBLs). To the authors' knowledge, this is the first description of the molecular epidemiology and the long-term dissemination of qAmpC-producing Enterobacteriaceae in Portuguese clinical settings, highlighting an evolution towards a more complex epidemiological situation regarding cephalosporin resistance in Portugal.
Introduction
Acquired AmpC β-lactamases (qAmpC) are an emerging cause of resistance to broad-spectrum cephalosporins among Enterobacteriaceae lacking inducible chromosomal AmpC genes, such as Escherichia coli , Klebsiella spp., Proteus mirabilis and Salmonella spp. [1] [2] [3] [4] . Genes encoding qAmpC are usually located on multidrug resistance plasmids, seriously constraining the therapeutic options against several infectious diseases [2] . qAmpCproducing Enterobacteriaceae have been reported worldwide, with significant geographical differences in the prevalence and epidemiology of different qAmpC types (Table 1) . According to the few surveillance studies available in Europe, CMY-2-like enzymes are the most widespread variants [1, 3, 4, 17, 18] (Table 1 ). In the present study, we investigated the occurrence, diversity and molecular epidemiology of qAmpC β-lactamases among Enterobacteriaceae species lacking inducible chromosomal AmpC genes recovered from Portuguese clinical settings over a 7-year period. Materials and methods
Bacterial isolates
We screened 675 isolates [Escherichia coli (n =480), Klebsiella pneumoniae (n =141), Klebsiella oxytoca (n = 27) and Proteus mirabilis (n =27)] non-susceptible to broad-spectrum cephalosporins identified from the clinical samples of patients attending four hospitals (HA, HB, HC, HD; n =572) and three community laboratories (CL1, CL2, CL3; n =103) located in the North and Centre of Portugal between 2002 and 2008. The geographic distribution of the surveyed clinical settings is shown in Fig. 1 . Bacterial identification and preliminary susceptibility testing were performed by using the automated VITEK (bioMérieux, Marcy l'Étoile, France) or Phoenix (BD Diagnostics, Sparks, MD, USA) systems.
Antimicrobial susceptibility and qAmpC characterisation
Antimicrobial susceptibility testing to β-lactam and non-β-lactam antibiotics was performed by using the standard disk diffusion method [32, http://www.eucast.org/]. Presumptive qAmpC producers were preliminarily identified using phenotypic criteria: (i) resistance to cefoxitin (FOX-R), intermediate susceptibility or resistance to amoxicillinclavulanic acid (AMC-I/R) and to at least one oxyiminocephalosporin (CEF-I/R); or (ii) susceptibility to cefoxitin (FOX-S), AMC-I/R, CEF-I/R and a negative double disk synergy test (DDST) (detailed below) [33] . The presence of genes coding for qAmpC enzymes (CMY, MOX, FOX, LAT, ACT, MIR, DHA, ACC) was further confirmed by polymerase chain reaction (PCR) using primers and conditions previously described [1, 34] and sequencing of both strands of each amplified bla gene.
Co-production of ESBLs
The production of extended-spectrum β-lactamases (ESBLs) was investigated among qAmpC-producing isolates by using the standard DDST performed with cefotaxime, ceftazidime, cefepime and aztreonam disks applied 20-30 mm apart from an amoxicillin-clavulanate disk [35] on Mueller-Hinton agar plates with and without cloxacillin (250 mg/L) (Sigma-Aldrich, St. Quentin-Fallavier, France). The characterization of ESBLs was performed by PCR using specific primers for bla TEM , bla SHV and bla CTX-M , and further sequencing [32] .
Conjugation experiments
Conjugation experiments were performed as previously described using E . coli BM21R (nalidixic acid and [32] . E . coli phylogenetic groups were identified by a multiplex PCR assay described by Clermont et al. [38] .
Results and discussion
One hundred (89 FOX-R, 11 FOX-S) presumptive qAmpC producers were identified, from which 50 (50 %) carried bla qAmpC genes (41 K . pneumoniae , 5 E . coli and 4 K . oxytoca). They corresponded to 56 % (50/89) of the FOX-R isolates and were mainly recovered from urine (38 %, 19/50) and respiratory samples (26 %, 13/50) of hospitalised patients. The remaining FOX-R isolates (n =39) were ESBL producers (85 %, 33/39) which might have porin modifications and/or possible chromosomal AmpC hyperproducers (E. coli; 62 %, 24/39) [2, 33] .
DHA-1 was the most prevalent qAmpC (94 %, 47/50), identified among K. pneumoniae (n =41; 12 PFGE types), K. oxytoca (n =4; 2 PFGE-types) and E. coli (n =2; 2 PFGEtypes) isolates from three hospitals (HA, HB, HC) and one community laboratory (CL1) since 2003 ( Table 2 , Fig. 2 ). Despite the high clonal diversity observed, three DHA-1-producing Klebsiella spp. clones were more frequently identi- (Table 2) . Moreover, the DHA-1-producing E. coli isolates (HA, HB) belonged to B1 and B2 phylogroups ( Table 2) . Although the B2 phylogroup accounts for most human infections involving cephalosporin-resistant strains [39] , DHA-1 has been previously reported in non-B2-E. coli clinical isolates (B1-, A-, or D-E. coli) [18, 40, 41] . The acquisition of virulence traits and multidrug resistance patterns (including to broad-spectrum cephalosporins) by A and B1 phylogroups, traditionally considered commensal, might contribute to their increasing identification among E. coli isolates causing human infections [38, [42] [43] [44] [45] ; Novais and Peixe, unpublished data].
The CMY-2 enzyme was detected in 6 % (3/50) of qAmpC producers, corresponding to diverse B1-E. coli recovered in different hospitals in 2006 and 2007 (Table 2) . Studies from France also report CMY-2 mainly in E. coli belonging to phylogroup B1 [12] , but in Canada, USA and Norway, it has been mostly associated with D-E. coli isolates [8, 18, 46] . The high occurrence of DHA-1 producers observed in this study resembles that reported in Asian countries (67-93 %) [2, 9, 10, 16] and contrasts with data from Europe (3-20 %; predominance of CMY-2-like enzymes) [2-4, 17, 19, 21] , a scenario probably reflecting the bias induced by the clonal dissemination of particular DHA-1-producing K . pneumoniae strains in Portuguese hospitals. Interestingly, the preliminary characterisation of presumptive qAmpC producers collected in 2012 indicated the maintenance of low levels of CMY-2-like enzymes and the predominance of DHA-1 in Portuguese clinical settings (Machado and Peixe, personal communication).
Isolates producing qAmpC were concomitantly resistant to kanamycin (98 %), tobramycin (96 %), sulphonamides (96 %), streptomycin (84 %), ciprofloxacin (82 %) and trimethoprim (3) KpB ( (3) HB (4) KpF (6) KpD (1), KpE (3) OXA-1 (6) SHV-12 + OXA-1 (4) Km,Tb,(Sm),(Gm),(Ak),Cp,Na,Su, (Tp),(Te),(Cm) 2008 HA (6) HB (4) KpF ( (80 %) ( Table 2) , as commonly observed [2] . Most isolates (94 %, 47/50; DHA-1 producers) co-expressed ESBLs belonging mainly to SHV (SHV-5, -12, -90, -145; n =19) types and/or OXA-1 (n =9/n =18), but also CTX-M-32 (n =1) ( Table 2 ). This study is the first, to the authors' knowledge, describing the co-production of DHA-1 and CTX-M-32 or highly related SHV-types. Although in Portugal an endemic situation of ESBL-encoding plasmids and clones [32, [47] [48] [49] [50] has been implicated in the high rates of resistance to broad-spectrum cephalosporins (one of the highest in Europe) [51, http://www. ecdc.europa.eu/en/publications/surveillance_reports/arhai/ Pages/arhai.aspx], the association of qAmpCs and ESBLs in different Enterobacteriaceae species reflects a more complex and problematic epidemiological situation regarding cephalosporin resistance in Portugal. In contrast to most studies, the transferability of bla qAmpC genes was only achieved in 2 % of the isolates (one CMY-2 producer) [2, 3] , which could be justified by the loss of tra genes (involved in plasmid conjugative transfer) or the mobilisation of bla qAmpC to the bacterial chromosome through integrative and conjugative elements (ICEs) [20] , but we cannot discharge the need for other experimental conditions [52] . Although our results suggest that the dissemination of bla qAmpC in Portugal occurred mainly through clonal spread, the presence of bla DHA-1 genes in different species highlights the involvement of lateral genetic transfer elements [3, 20] .
This study constitutes the first report describing the molecular epidemiology and long-term dissemination of qAmpC enzymes among Enterobacteriaceae (frequently coproducing ESBLs) in Portuguese clinical settings, at least since 2003. In contrast with other European countries, DHA-1 was the most frequent variant mainly associated with the spread of several Klebsiella spp. clones. The recent implementation of an epidemiological surveillance system of antimicrobial resistance and a stricter control on antibiotic use in Portuguese clinical institutions (http://www.dgs.pt/upload/ membro.id/ficheiros/i018596.pdf) should contribute to the improvement of measures to contain the emergence and spread of these multidrug-resistant strains. Finally, deeper studies are needed in order to address the contribution of mobile genetic elements and/or particular lineages for the dissemination of acquired AmpC β-lactamases in Portugal.
